In this article, we will look at the 10 Best American Stocks to Buy and Hold for the Next Decade.
American stocks are getting a closer look as investors try to separate long-term compounders from names that simply rode the latest market rally. The U.S. market still has heavy exposure to AI, cloud, software, semiconductors, payments, health care, and industrial automation, but the case for buying and holding is becoming more stock-specific. A decade-long view depends on earnings durability, reinvestment capacity, and balance-sheet strength, not just recent price momentum.
BlackRock says the key takeaway from recent U.S. earnings is that “Earnings strength is broadening,” with the S&P 500 excluding the Mag Seven “on pace for 17% earnings growth in Q1.” Capital Group makes a similar point, saying markets are moving toward “a more balanced one with a broadening opportunity set.” Janus Henderson adds that “The outlook for U.S. large-cap equities remains positive,” supported by “a broad capital investment cycle, productivity gains, and expectations for double-digit earnings growth.” In summary, the U.S. equity story is no longer just about a handful of mega-cap winners. The long-term setup is where earnings growth, productivity gains, and scale reinforce each other.
Against this backdrop, American stocks with strong growth prospects deserve a closer look. With that in mind, let’s take a look at the 10 Best American Stocks to Buy and Hold for the Next Decade.
Pixabay/Public Domain
Our Methodology
We used the Finviz screener to identify American stocks that are forecasted to grow their earnings by over 20% annually in the next 5 years and carry a Buy or better rating from analysts. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
10. Analog Devices, Inc. (NASDAQ:ADI)
On May 26, 2026, JPMorgan raised the firm’s price target on Analog Devices, Inc. (NASDAQ:ADI) to $450 from $400 and maintained an Overweight rating on the shares. JPMorgan said the company reported a “strong beat-and-raise” quarter on broad-based strength and called Analog Devices its top pick in the diversified semiconductor segment.
On May 21, 2026, Raymond James raised the firm’s price target on Analog Devices, Inc. (NASDAQ:ADI) to $430 from $385 and maintained an Outperform rating on the shares. Raymond James said Analog Devices delivered another strong quarter, with accelerating AI-driven data center demand accounting for most of the communications revenue. The firm also cited the acquisition of Empower Semiconductor, which expands the company’s AI and data center power exposure.
A day earlier, Analog Devices, Inc. (NASDAQ:ADI) reported Q2 adjusted EPS of $3.09, ahead of the consensus estimate of $2.90. Revenue totaled $3.62B, above the consensus estimate of $3.51B. CEO and Chair Vincent Roche said ADI’s second-quarter revenue and earnings were above the high end of its outlook, reflecting “record demand” and operational discipline.
Analog Devices, Inc. (NASDAQ:ADI) designs, manufactures, tests, and markets integrated circuits, software, and subsystem products globally.
9. CrowdStrike Holdings, Inc. (NASDAQ:CRWD)
On May 29, 2026, Jefferies analyst Joseph Gallo raised the firm’s price target on CrowdStrike Holdings, Inc. (NASDAQ:CRWD) to $775 from $500 and maintained a Buy rating on the shares. Gallo expects CrowdStrike to report a Q1 beat but noted that expectations have risen after the recent share rally. Jefferies said CrowdStrike can meet investor expectations for $275M of net new annual recurring revenue in Q1, though near-term share performance may be “muted” unless Q2 and fiscal 2027 guidance support ARR growth acceleration into the second half of the year.
On May 28, 2026, CrowdStrike Holdings, Inc. (NASDAQ:CRWD) announced the next evolution of Project QuiltWorks, extending the framework from securing frontier AI risk to mitigating financial exposure. The company said cyber insurance leaders, including Coalition, Liberty Mutual Insurance, Lockton, Resilience, and Marsh, are bringing actuarial intelligence, underwriting expertise, and financial protection to the framework.
A day earlier, Oppenheimer raised the firm’s price target on CrowdStrike Holdings, Inc. (NASDAQ:CRWD) to $750 from $500 and maintained an Outperform rating, citing checks that pointed to potential upside versus Q1 2027 consensus revenue estimates.
Benchmark analyst Yi Fu Lee also raised the firm’s price target on CrowdStrike Holdings, Inc. (NASDAQ:CRWD) to $700 from $500 and maintained a Buy rating, saying the company is “highly likely” to exceed Q1 consensus expectations across ARR, revenue, operating income margin, and free cash flow margin.
CrowdStrike Holdings, Inc. (NASDAQ:CRWD) provides cybersecurity solutions in the United States and internationally through a cloud-delivered SaaS platform.
8. Marvell Technology, Inc. (NASDAQ:MRVL)
On May 28, 2026, Raymond James raised the firm’s price target on Marvell Technology, Inc. (NASDAQ:MRVL) to $235 from $105 and maintained a Strong Buy rating on the shares. Raymond James said Marvell’s Q1 results showed continued strength and accelerating momentum, led by data center growth in custom compute and optical interconnect. The firm also noted that management raised FY27-FY28 guidance, even as shares traded roughly flat after the call.
Rosenblatt analyst Kevin Cassidy also raised the firm’s price target on Marvell Technology, Inc. (NASDAQ:MRVL) to $240 from $190 and maintained a Buy rating on the shares. Cassidy said Marvell delivered “a somewhat muted beat and raise,” with upside clouded by higher operating expenses, share dilution from the Celestial AI acquisition, and a gross margin headwind in calendar 2027 from the Custom AI ASIC ramp.
Similarly, Benchmark raised the firm’s price target on Marvell to $275 from $130 and maintained a Buy rating. Benchmark said the stock’s move looked more like “valuation and expectations digestion” than a negative readthrough on demand, while calling the higher FY27/FY28 revenue path the stronger message.
On May 27, 2026, Marvell Technology, Inc. (NASDAQ:MRVL) reported Q1 adjusted EPS of 80c, ahead of the consensus estimate of 79c. Revenue totaled $2.418B, above the consensus estimate of $2.41B. Chairman and CEO Matt Murphy said Marvell delivered record first-quarter fiscal 2027 revenue, up 28% year-over-year, and guided second-quarter revenue to $2.7 billion at the midpoint. Murphy said the company is seeing “exceptional AI-related bookings,” driving a higher revenue outlook for both fiscal 2027 and fiscal 2028.
Marvell Technology, Inc. (NASDAQ:MRVL), together with its subsidiaries, provides data infrastructure semiconductor solutions in the United States and internationally.
7. Welltower Inc. (NYSE:WELL)
On May 26, 2026, BofA raised the firm’s price target on Welltower Inc. (NYSE:WELL) to $277 from $260 and maintained a Buy rating on the shares. BofA updated its models following Q1 earnings from healthcare REITs.
Scotiabank also raised the firm’s price target on Welltower Inc. (NYSE:WELL) to $248 from $236 and maintained an Outperform rating on the shares. Scotiabank said it was updating price targets for U.S. Real Estate & REITs under its coverage following Q1 results. The firm cited a “robust start” to the year for NYC office leasing, while noting mixed multifamily rent growth across the Sunbelt.
UBS also raised the firm’s price target on Welltower Inc. (NYSE:WELL) to $249 from $240 and maintained a Buy rating, saying both internal and external growth remain elevated and show no signs of slowing.
Last month, Welltower Inc. (NYSE:WELL) reported Q1 normalized FFO of $1.47, ahead of the consensus estimate of $1.45. Revenue totaled $3.35B, above the consensus estimate of $3.2B. The company also reported total portfolio year-over-year SSNOI growth of 16.4%, driven by 22.1% SSNOI growth in its Seniors Housing Operating portfolio.
Welltower Inc. (NYSE:WELL) focuses on rental housing for aging seniors across the United States, the United Kingdom, and Canada.
6. Eli Lilly and Company (NYSE:LLY)
On May 31, 2026, Eli Lilly and Company (NYSE:LLY) announced results from the Phase 3 Libretto-432 clinical trial of Retevmo as adjuvant therapy versus placebo in patients with early-stage rearranged during transfection fusion-positive non-small cell lung cancer. The study met its primary endpoint, showing a “highly statistically significant and clinically meaningful” improvement in investigator-assessed event-free survival. Eli Lilly said selpercatinib reduced the risk of disease recurrence or death by 83% versus placebo in the primary analysis population.
On May 28, 2026, Eli Lilly and Company (NYSE:LLY) said all three of the nation’s largest pharmacy benefit managers will cover its full obesity medicine portfolio, expanding access to FDA-approved options through existing insurance. Coverage from CVS Caremark (CVS) Commercial Template begins June 1 for Foundayo, while current Zepbound patients will continue to have uninterrupted coverage and broader access across template plans by October 1. Eli Lilly said eligible commercially covered patients can access both medicines for as little as $25 per month, while Medicare Part D beneficiaries may be eligible to pay $50 per month beginning July 1 through the Medicare GLP-1 Bridge program.
On May 26, 2026, BofA raised the firm’s price target on Eli Lilly and Company (NYSE:LLY) to $1,251 from $1,133 and maintained a Buy rating on the shares. BofA said Lilly’s overall revenue and profit growth should be driven by a doubling of GLP-1 U.S. market sales by 2033.
Eli Lilly and Company (NYSE:LLY) discovers, develops, manufactures, and markets human pharmaceutical products internationally.
While we acknowledge the potential of LLY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LLY and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Best American Stocks to Buy and Hold for the Next Decade.
Disclosure: None. Follow Insider Monkey on Google News.
